Array Biopharma, Inc. (ARRY) Posts Q3 Loss of 20c/Share

Array Biopharma, Inc. (NASDAQ: ARRY) reported Q3 EPS of ($0.20), $0.01 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $9.4 million.

For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.

You May Also Be Interested In

• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Dawson Geophysical (DWSN) Reports Q2 Loss of $0.11
• Celcuity (CELC) Misses Q2 EPS by 28c